Dose Insider / Glossary / Switching

SwitchingHow the labels handle a move between GLP-1 medicines

Updated November 20, 2026 路 3 min read 路 WEGOVY, OZEMPIC, RYBELSUS and ZEPBOUND labels, 2026

Switching means moving from one GLP-1 medicine to another, or from one form of the same medicine to another, such as from a weekly injection to a daily tablet. The labels set exact rules for some moves within a brand family.

62%Day 7, semaglutide left after last dose
Semaglutide left after last doseShare of the usual peak, label half-life modelDay 762%Day 1431%Day 2116%Day 288%Semaglutide left after lastdoseShare of the usual peak, label half-life modelDay 762%Day 1431%Day 2116%Day 288%

Zepbound starts at 2.5 mg whatever came before.

On this page

For the most common move between molecules, from Wegovy to Zepbound, there is no special rule: Zepbound starts at 2.5 mg for everyone.1,2,3

Moves the labels spell out

FromToWhen
Wegovy injection 2.4 mgWegovy tablets 25 mgOne week after the last injection
Wegovy tablets 25 mgWegovy injection 2.4 mgThe day after the last tablet
Ozempic injection 0.5 mgRybelsus 7 or 14 mg, or Ozempic tablets 4 or 9 mgOne week after the last injection
RybelsusOzempic tablets, or backThe day after the last tablet, not in the first 30 days

WEGOVY label section 2.5; RYBELSUS and OZEMPIC tablets label sections 2.3 and 2.4.1,2

Two details stand out. A Wegovy tablet user who did not tolerate 25 mg can be moved to the 1.7 mg injection instead. And between Rybelsus and Ozempic tablets the label gives its own matching table, 7 mg with 4 mg and 14 mg with 9 mg, because the two tablets are not substitutable milligram for milligram.1,2 These are the label's rules, and the prescriber applies them.

Moves the labels leave open

The labels of semaglutide and tirzepatide do not describe moving from one to the other. The Zepbound label has a single starting dose for every user, 2.5 mg a week for 4 weeks, and says this dose is for starting treatment, not for staying on. It also says Zepbound should not be combined with another tirzepatide product or with any GLP-1 receptor agonist, and the Wegovy label says the same about combining it with other GLP-1 receptor agonists.2,3 So the old medicine is stopped and the new one starts at its own first step.

The old medicine does not vanish on the day of the switch. The Ozempic label says semaglutide stays in the circulation for about 5 weeks after the last dose.4 Using the label's half-life of about 1 week, our model puts the level left at about 62% of its usual peak 7 days after a last weekly dose. It falls to 31% at day 14, 16% at day 21 and 8% at day 28. Those weeks overlap the four weeks on Zepbound's starting dose. Our page on switching from Wegovy to Zepbound draws both curves and gives the dates.

Why people switch

The reasons are usually cost, coverage, side effects or results. The only trial that assigned people to one or the other, SURMOUNT-5, found a weight loss of 20.2% on tirzepatide against 13.7% on semaglutide over 72 weeks in 751 adults with obesity. It was open-label and funded by the maker of tirzepatide.5 The approved uses also differ. Wegovy is approved to lower heart risk in adults with heart disease and excess weight, a use Zepbound does not have, so a person on Wegovy for that reason should not assume the switch is like for like.2,3

What to watch after a switch

Sources

  1. RYBELSUS and OZEMPIC (semaglutide) tablets prescribing information, revised January 2026. Novo Nordisk; DailyMed, version published August 19, 2026; sections 2.3 and 2.4. dailymed.nlm.nih.gov
  2. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 1 and 2.5. accessdata.fda.gov
  3. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 1, 2, 6.1 and 8.3. accessdata.fda.gov
  4. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 2.1 and 12.3. accessdata.fda.gov
  5. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025;393:26-36. nejm.org

Related analyses

Log the last dose of the old medicine and the first of the new, and see both on one chart.

Open Dose Insider